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Abstract  
 
Comparing the efficacy of different treatments in psychiatry is difficult for many reasons, even when 
they are investigated in ‘head-to-head’ studies. A consensus meeting was, therefore, held to produce 
best practice guidelines for such studies. This article presents the conclusions of this consensus and 
illustrates it using published data in the field of antidepressant treatment of generalized anxiety 
disorder.  
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Introduction  
 
The issue of non-inferiority when comparing different drugs or other treatment modalities in 
medicine has for many years been very contentious. Most previous claims of comparable 
efficacy between treatments have been complicated by the fact that a lack of statistical power 
can lead to apparent non-difference in outcome that may well be falsely assumed to imply 
non-inferiority. Moreover, there is no generally accepted methodology for establishing claims 
of non-inferiority in such comparative studies. In order to overcome these problems, in 
September 2005 the authors of this article met as a panel of experts in the relevant areas, 
namely anxiety disorders, clinical trials and statistics. The objective was to provide a set of 
consensus guidelines on how to conduct non-inferiority trials.  
 
To take advantage of the current practice and clinical evidence literature, the group focused 
on one psychiatric disorder, generalized anxiety disorder (GAD). The published data from 
GAD placebo-controlled trials provided established efficacy estimates to guide discussions 
regarding non-inferiority comparisons (Appendix). In addition, there were comparative 
studies of two drug treatments soon to be forthcoming, thus providing a prospective test of the 
utility and practicality of the consensus output (Allgulander, et al., 2001) The principles, 
however, are relevant to all psychiatric disorders and treatments, and therefore this paper 
should have wide applicability.  
 
A non-inferiority trial provides the opportunity to evaluate the efficacy of a new treatment vs. 
a well-known treatment with established efficacy. Typically, a ‘test’ treatment is compared 
with a treatment that is already approved and/or widely used by practicing physicians. The 
objective of a non-inferiority clinical trial is to establish that the new treatment is not worse 
than the active control by more than a pre-specified non-inferiority margin (also referred to as 
the maximum clinically irrelevant difference or delta). In other words, the new treatment is 
shown to be as effective or no worse than the active control based upon an a priori defined 
clinically appropriate response measure. It is also important that the comparator should be 
superior to placebo in the corresponding trial.  
 
The consensus meeting and subsequent discussions reviewed a series of issues that bear on 
the validation of a non-inferiority trial. These are discussed separately below and include 
consideration of regulatory, statistical and clinical issues, such as the sensitivity of the 
measure, clinically meaningful differences between treatments and sample size (Gotzsche 
2006).   
 
Identification of the non-inferiority margin  
 
The EMEA (The European Medicines Agency) requires clinical trials with the comparison of 
a test product with an authorized standard product in an adequate dose (EMEA guidance for 
GAD). For our purposes, we considered the development of guidelines for non-inferiority 
with a newly approved treatment, duloxetine, with the established or reference treatment of 
venlafaxine XR, an antidepressant that has been approved for the treatment of GAD in the 
dose range used in these duloxetine comparator studies.  
 
The issue here is: what is an appropriate clinically meaningful margin of non-inferiority for 
duloxetine vs. venlafaxine in the treatment of GAD? This margin is the largest difference that 
is judged to be clinically acceptable and cannot be greater than the smallest effect size that the 
active drug would be expected to have compared with placebo in the setting of a planned trial 
(ICH E10 guidelines). The choice of measure for this is open – it could be either doctor- or 
patient-related scales or differences in response or remission rates.  
 
Given that the preponderance of efficacy data in GAD trials has been collected using the 
Hamilton Anxiety Rating Scale (HAMA), those present at the consensus meeting agreed to 
use these scores in the worked example.  
 
In placebo-controlled (superiority) trials, a statement is made in advance regarding the 
minimum difference between the active treatment and placebo that would be considered 
clinically important. The sample size calculation for a placebo-controlled superiority trial 
requires a reasonable chance (power) of detecting this ‘target’ difference in the primary 
efficacy measure for the test treatment vs. placebo. The observed difference together with the 
95% confidence interval for the difference would then be used to provide an estimate of the 
improvement in efficacy seen with the test treatment. The observed data should then be 
compared with the clinically important value to determine whether the active treatment 
provides at least this minimum improvement, with in particular the confidence interval 
clinically interpreted in the light of the pre-specified target difference.  
 
In non-inferiority trials, the ‘target’ difference is much more difficult to specify because the 
comparison is between two active treatments, and therefore what constitutes minimal 
improvement is more subjective. In other words, determining the non-inferiority margin is 
much more difficult and potentially contentious. In the past, the non-inferiority margin was 
sometimes set to be a proportion (one-third to one-half) of the observed difference between 
the active comparator and placebo (possibly that found from meta-analysis of placebo-
controlled trials). This was based on the reasoning that the test treatment would then be shown 
to be closer to the comparator than to placebo. However, the establishment of a non-
inferiority margin cannot be based purely on statistical criteria because the uncertainty 
associated with the selected margin is not statistically measurable (Hung, et al., 2003). The 
EMEA Points to Consider on the Choice of Non-Inferiority Margin (page 2) also states: ‘Such 
an approach [taking a proportion of the superiority margin] does not necessarily even ensure 
superiority over placebo and has no clinical rationale to support it. The choice of delta must 
always be justified on both clinical and statistical grounds’. Therefore, clinical relevance 
together with statistical reasoning is essential to establish the non-inferiority margin. The ICH 
E9 guidelines state that the choice of a clinically acceptable non-inferiority margin needs 
justification with respect to its meaning for future patients and should be smaller than 
differences observed in superiority trials of the active comparator vs. placebo.  
 
Although there is no gold standard in determining a non-inferiority margin, the approach 
taken in the consensus meeting was to first identify an appropriate clinically meaningful drug-
placebo difference on the primary efficacy variable. Once the drug-placebo difference is 
identified, this information can be used to assist in the identification of a ‘no less effective or 
no worse than’ difference between two active treatments.  
 
Statistical methods  
 
In the analysis of a non-inferiority trial, a point estimate is calculated for the difference in 
efficacy between the test product and the active comparator. This represents the best estimate 
of the true difference. The 97.5% one-sided confidence interval is used to both provide an 
interval estimate for this difference and to investigate the null hypothesis that the difference in 
efficacy between the test product and the active comparator (in this case, duloxetine vs. 
venlafaxine) is no worse than the prespecified margin, vs. the alternative hypothesis that the 
true difference is greater than this target. Figure 1 represents the confidence interval approach 
to analysis of non-inferiority trials. The lower limit of the 97.5% confidence interval is used to 
determine whether a difference between the two products greater than the pre-set non-
inferiority margin can be excluded with sufficient confidence. If the non-inferiority margin is 
excluded from the 97.5% one-sided confidence interval, then it can be concluded that the test 
product (duloxetine) is not inferior to the active comparator (venlafaxine).   
 
The point estimate may even indicate that the test product (duloxetine) has better efficacy 
than the active comparator (venlafaxine); however, if the confidence interval is wide as result 
of high variability and/or insufficient sample size and includes the non-inferiority margin, 
then inferiority of the test product cannot be excluded.  
 
Trial criteria that will allow a fair assessment of non-inferiority  
 
There are many aspects of trial design and analysis that can influence a non-inferiority 
assessment. These include: the nature of the comparator studies; whether a placebo group is 
included; the relative outcome of each active arm compared with placebo and the overall 
response rate in the trial. Following discussion, the consensus committee’s view was that for a 
test intervention to be considered as potentially non-inferior (NI) to an active (licensed) 
comparator, the following conditions are all required to be met:  
 
1) There is at least one three-arm double-blind placebo-controlled comparison trial for the test 
intervention with an active comparator.  
 
2) Both test intervention and active comparator must be superior to placebo by a clinically 
meaningful difference [For the HAMA this would be at least a (baseline corrected) change of 
≥2 points at endpoint compared with placebo at 8 weeks. This figure of 2 is based on the 
range of deltas in the venlafaxine GAD studies see Figure 2].  
 
3) The ‘responder rates’ [defined as a >50% reduction in HAMA] should be different by at 
least 10% points, e.g. if 30% for placebo then they would need to be >40% for active 
comparator and test intervention.  
 
4) There should be reasonable evidence that both the active comparator and the test 
intervention are better than placebo on the primary outcome measure in the trial (P < 0.05 in 
each case). (In particular, if the test intervention does not separate from placebo but active 
comparator does, then the test intervention has failed).  
 
Once these initial criteria have been met, it is then possible to consider the test intervention to 
show non-inferiority compared with the active comparator, if the following additional two 
conditions are both met:  
 
1) The difference between the active comparator and the test intervention is <50% of 
difference between the active comparator and placebo, and this difference is not clinically 
meaningful [e.g. not more than 1.5 HAMA points].  
 
2) The responder rate of the test intervention is not more than 5% points lower than that of the 
active comparator. [For the HAMA, the rationale for the delta of 1.5 is on three grounds: 
firstly, it is (just) below the lower limit of the range of previously observed differences in 
mean HAMA between venlafaxine and placebo; secondly, figures below this would be 
virtually impossible to justify on clinical grounds and thirdly, from Figure 2 of the Appendix 
corresponds approximately to a 5% point difference in responder rates, which in turn is also 
considered a minimum for NI as stated above.]  
 
Other necessary criteria  
 
In addition, there are a number of other criteria that must be met:  
 
1) Dosing must be proportionate to the known efficacy of each drug (noting that any 
conclusions drawn from a non-inferiority analysis only apply to the doses of drugs tested).  
 
2) Treatment duration must be appropriate to the known pharmacological actions of the drug 
(see comment on benzodiazepines in point 6 below).  
 
3) The sample size of the study must be such that it has a reasonable power of obtaining a 
lower confidence limit that exceeds delta [see Statistics section above].  
 
4) There are no age, gender or other major prognostic imbalances between the groups (despite 
randomization).  
 
Additional considerations  
 
In addition to these main criteria, a number of other considerations and observations were 
made:  
 
1) Either a flexible or fixed dose treatment design could be used.  
 
2) Distortions due to markedly different speed of therapeutic response between different 
classes of drug should be avoided as far as possible. Thus comparing a fast-acting drug , such 
as a benzodiazepine with an antidepressant in GAD would be unduly influenced if the 
outcome measures were taken at the time of the onset of benzodiazepine efficacy.  
 
3) Minimal mean entry level of severity should be at least in the moderately ill range. A 
suggestion of a score of >20, ideally at least 22, on the HAMA was recommended.  
 
4) One could use for the outcome comparisons a change score on questions that measure core 
symptoms of the illness e.g. item 1 on the HAMA. It would also be acceptable to use changes 
in a subscale – e.g. that for worry anxiety tension, although a lesser range of scores may 
reduce power and may compromise reliability.  
 
5) Disorder-specific scales may offer greater power – e.g. GADI for GAD (Argyropolous, et 
al., 2007). Trials in other disorders may of course use other scales that are specifically 
relevant to that disorder.  
 
6) Remission should be considered as an alternative and potentially more secure endpoint (but 
this is hard to reach with GAD though longer trial duration may achieve this).  
 
7) The choice of analytical models may well be influential – for example, a ‘last observation 
carried forward’ (LOCF) approach to missing data will widen confidence intervals due to high 
scoring losses to follow-up, and observed/complete case analysis may overestimate the 
efficacy of interventions with high attrition rates. Sensitivity analyses employing various 
approaches including multiple imputation may be preferable.  
 
8) Studies should include compliance evaluations to ensure that compliance levels in the 
different groups cannot explain any observed difference in efficacy and to ensure that 
compliance is sufficiently good to avoid a general bias.  
 
9) Consideration should be given to methods to minimize measurement error in the primary 
efficacy measure. Methods to minimize measurement error in the HAMA, such as careful 
training and certification of HAMA raters, should always be considered.  
 
Conclusions  
 
Non-inferiority studies are likely to assume greater importance in psychiatry as healthcare 
providers seek to optimize treatment provision. This article sets out the results of an expert 
consensus meeting that addressed this issue using the worked example of antidepressant 
efficacy in GAD. The conclusions will hopefully provide a basis for other such studies 
involving various treatments and disorders.  
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Appendix Published data on approved GAD medications  
One approach to identify a non-inferiority margin is to assess the full range of established 
differences in mean changes of the HAMA total score vs. placebo that were used as evidence 
of a clinically relevant improvement in efficacy for the medications approved for the 
treatment of GAD. Three medications have been approved in Europe for the treatment of 
GAD (venlafaxine, paroxetine and escitalopram). The published literature on these 
medications in GAD has shown difference between active drug and placebo in mean change 
in HAMA total score from baseline ranging from 1.1 to 5.4 (Tables 1 and 2). After 8 weeks of 
treatment, venlafaxine differences in mean values ranged from 1.7 to 4.4 with an overall mean 
difference of 2.7 (all doses). With paroxetine differences ranged from 2.1 to 3.2 with an 
overall mean difference of 2.7, escitalopram differences ranged from 2.0 to 3.9 with an 
overall mean difference of 2.8. While most of the studies showed evidence of differences 
compared with placebo, the range of differences in mean values across the studies is large. 
Focusing on venlafaxine, these studies have shown differences in mean values in HAMA total 
score ranging from 1.7 to 5.4 points. The difference in responder rates (based on the reduction 
in HAMA total score) ranged from 8% to 29%.  
 
Another approach to identifying a non-inferiority margin would be to examine the meaning of 
differences in HAMA change scores of various magnitudes. Logistic regression analysis was 
used to predict drug-placebo differences in HAMA response rates utilizing drug-placebo 
HAMA change score differences. The regression analysis was performed because response is 
a dichotomous variable and this type of data tends to be nonlinear. The varying sample sizes 
in these three studies are also taken into account in the analysis.  
 
Included in this analysis were acute phase drug-placebo HAMA response rates and HAMA 
mean changes (from baseline to endpoint) for all active drug comparisons with placebo in 
three venlafaxine studies (Davidson, et al., 1999; Allgulander, et al., 2001; Gelenberg, et al., 
2000). Unfortunately, HAMA response rate data was not provided for paroxetine and 
escitalopram studies. With various dosages of venlafaxine included in these studies, a total of 
six comparisons with placebo were available. The Gelenberg study used a 40% or greater 
decrease from baseline to define clinical response, whereas the other two studies used a 50% 
or greater decrease from baseline. Placebo responder rates across the three studies were 36%, 
40% and 42%. To perform the regression analysis, a fixed value of 40% for the placebo 
response rate was assumed.  
 
Figure 2 displays the actual study results, the predicted values based on the regression model, 
and 95% confidence intervals around the predicted values. Using this regression model, we 
can estimate HAMA response rate differences at various levels of HAMA change differences. 
For example, a HAMA change difference between two treatments of three points would 
correspond to approximately a 17% difference in the response rates between the treatments. A 
HAMA change difference of two points corresponds to a HAMA responder rate difference of 
about 10%.   
 
A similar analysis was performed using HAMA changes and response rates based on the 
Clinician’s Global Impression – Improvement (CGI-I) scale (CGI-I response of 1 or 2) using 
data from the three approved medications. Data from six studies based upon the three 
approved medications were included in the analysis (Davidson, et al. 1999; Allgulander, et al. 
2001; Lenox-Smith & Reynolds, 2003; Pollack, et al. 2001; Rickels, et al. 2003; Davidson et 
al. 2004). Placebo response rates across the six studies were 39%, 44%, 37%, 47%, 46% and 
38%. To perform the analysis, a fixed value of 40% for the placebo response rate was 
assumed.  
 
Figure 3 displays the actual study results, the predicted values based on the logistic regression 
model, and 95% confidence intervals around the predicted values. Using this regression 
model, we can estimate CGI-I response rate differences at various levels of HAMA change 
differences. For example, a HAMA change difference between two treatments of three points 
would correspond to approximately a 23% difference in the response rates between the 
treatments. A HAMA change difference of two points corresponds to a HAMA responder rate 
difference of about 19%. Note that the association between the difference in HAMA mean 
changes and the difference in CGI-I response rates was not very strong so the analysis of the 
CGI-I data is not of great help in identifying the non-inferiority margin for the HAMA mean 
difference.   
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